Protocol Ledger

NCT04091945 · Phase II · COMPLETED

A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS

Interventional Phase II clinical trial protocol NCT04091945 sponsored by Lumosa Therapeutics Co in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-01-27 Enrollment: 24 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04091945
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)24 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04091945
Protocol FieldVerified Registry Value
NCT IdentifierNCT04091945
Consolidated Lead SponsorLumosa Therapeutics Co
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment24 participants (ACTUAL)
Registered Start Date2020-01-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI